The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network
Ms. Green has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Director, Continuing Education, has disclosed that she has no relevant financial relationships.
Ann Gianola, MA, Manager, Continuing Education Accreditation & Program Operations, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, has disclosed that she has no relevant financial relationships.
Maria Ho, PhD, Oncology Scientist/Senior Medical Writer, has disclosed that she has no relevant financial relationships.
KielMJVelusamyTBetzBL. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med2012;209:1553–1565.
SamowitzWSSweeneyCHerrickJ. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res2005;65:6063–6069.
MarchettiAFelicioniLMalatestaS. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol2011;29:3574–3579.
PaikPKArcilaMEFaraM. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol2011;29:2046–2051.
GrishamRNIyerGGargK. Braf mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer2013;119:548–554.
ChapmanPBHauschildARobertC. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med2011;364:2507–2516.
GreavesWOVermaSPatelKP. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn2013;15:220–226.
SuFVirosAMilagreC. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med2012;366:207–215.
BalchCMSoongSJSmithT. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol2001;8:101–108.
XiLAronsENavarroW. Both variant and ighv4-34–expressing hairy cell leukemia lack the BRAF V600E mutation. Blood2012;119:3330–3332.
ChampionKJBunagCEstepAL. Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome. Clin Genet2011;79:468–474.